Coegin Pharma AB has appointed Professor Desmond J. Tobin, a prominent expert in skin and hair pigmentation science, as a Scientific Advisor. Prof. Tobin, a co-inventor of Coegin's skin pigmentation peptide NPP-4, has extensive research experience in melanocyte and hair-follicle biology, contributing significantly to the understanding of these fields. He will advise Coegin on their skin-pigmentation peptide NPP-4 and hair-growth assets. Additionally, Professors Anna Hultgårdh Nilsson and Jan Nilsson from Lund University, both key figures in Coegin's peptide platform, serve as strategic advisors. Coegin Pharma, a Swedish biotech company, focuses on innovations for hair and skin, including the commercialized hair growth product Follicopeptide®. The company is listed on NGM Nordic SME and Börse Stuttgart and is based in Lund, Sweden.

Coegin Pharma AB has completed its first commercial delivery of hair growth products based on Follicopeptide® to Hårklinikken, an international provider of specialized hair and scalp treatments. This delivery is a significant step in Coegin's commercial expansion, following a similar delivery to Gents. The partnership with Hårklinikken enhances Coegin's presence in the professional segment, where products are introduced through experts and clinics. The successful delivery demonstrates Coegin's capability to supply multiple commercial partners and aligns with professional market standards. CEO Jens Eriksson views this as a milestone and an endorsement of Coegin's science. The company continues to work with partners to establish Follicopeptide as a leading solution in premium and professional hair growth markets. Coegin Pharma, a Swedish biotech company, is known for its innovations in hair and skin, and is listed on NGM Nordic SME and Börse Stuttgart.

Coegin Pharma AB has announced the successful production and delivery of its first commercial batch of hair growth products based on Follicopeptide® to Gents, a leading Nordic grooming retailer. The pre-order batch sold out rapidly, highlighting strong consumer interest before the full market launch planned for January 2026. This milestone marks Coegin's transition from development to commercial operations, with CEO Jens Eriksson noting the validation of their product and strategy. Coegin plans further deliveries, including to Hårklinikken, strengthening its presence in premium distribution channels. The company aims to establish Follicopeptide as a leading solution in the premium hair growth market. Coegin Pharma is a Swedish biotech company focused on hair and skin innovations, currently commercializing Follicopeptide® globally and developing a new peptide for skin pigmentation regulation. Coegin is listed on NGM Nordic SME and Börse Stuttgart, with headquarters in Lund, Sweden.

The Nomination Committee for Coegin Pharma's 2026 Annual General Meeting has been appointed following the guidelines set at the 2025 Annual General Meeting. The committee members are Johan Arver (Chair), Martin Tisell, Rune Löderup, and Eva Sjökvist Saers. Their responsibilities include preparing proposals for the meeting regarding various roles and fees, as well as potential changes to the committee's guidelines. The meeting is scheduled for May 21, 2026, in Lund, Sweden. Shareholders can submit proposals by January 15, 2026, via email. The committee's proposals will be available in the meeting notice and on the company's website. Coegin Pharma, a Swedish biotech company, focuses on hair and skin innovations and is listed on NGM Nordic SME and Börse Stuttgart. More information is available on their website.

Coegin Pharma AB has announced that starting November 16, customers can pre-order the Gents Power Hair Activating Formula, marking a significant commercial milestone as the first Follicopeptide-based consumer product becomes available for purchase. Deliveries are expected to begin in December 2025. The product, developed in collaboration with Swedish retailer Gents, aims to enhance hair density and improve scalp health. Coegin's CEO, Jens Eriksson, expressed pride in reaching this milestone, emphasizing the transition from research to consumer availability. Gents' CEO, Jenny Rydhström, highlighted the excitement surrounding the product, noting its scientific basis in hair care. This launch is part of Coegin's strategy to globally commercialize its Follicopeptide-based innovations, showcasing its ability to move from development to market. Coegin Pharma is a Swedish biotech company focused on hair and skin innovations, with its shares listed on NGM Nordic SME and Börse Stuttgart. Gents is a Swedish retailer specializing in premium men's grooming products.

Coegin Pharma AB has announced the completion of a new complementary product for its Follicopeptide line, aimed at strengthening hair and enhancing product performance. This add-on, expected to launch by March 2026, is part of Coegin's strategy to expand its Follicopeptide ecosystem commercially. The product is designed to improve scalp receptiveness and user experience, offering potential for increased profitability and brand loyalty. Positive feedback has been received from partners, indicating commercial interest. Coegin Pharma is a Swedish biotech company known for innovations in hair and skin care, with its shares listed on NGM Nordic SME and Börse Stuttgart.

Coegin Pharma AB has partnered with Hårklinikken, a global leader in hair and scalp health, through a non-exclusive limited purchase order to commercialize Coegin's hair growth innovation, Follicopeptide®. This collaboration aims to introduce the product to a premium international audience by leveraging Hårklinikken's extensive clinical experience and global presence. Hårklinikken will launch the first Follicopeptide-based product under its label in early 2026, aligning with Coegin's strategy for accelerated market entry. Management from both companies expressed optimism about the partnership, highlighting the synergy between Coegin's scientific innovation and Hårklinikken's reputation and customer reach. Coegin Pharma, a Swedish biotech company, focuses on hair and skin innovations and is listed on NGM Nordic SME and Börse Stuttgart. Hårklinikken, with over 33 years of research, is known for its customized treatments and global clinics.

Coegin Pharma AB has announced the establishment of its own production facility in Denmark, aimed at enhancing production capacity, quality control, and cost efficiency for both commercial and R&D operations. Test production began in September, with commercial production of Follicopeptide® products set to start in October 2025. The facility allows Coegin to secure its supply chain, reduce dependency on external partners, and manage risks, while also providing access to a collaborative ecosystem in Denmark. CEO Jens Eriksson highlighted the strategic importance of the facility for controlling production timelines, quality, and costs. The setup is designed for scalability and cost-effectiveness, supporting Coegin's growth ambitions. Dr. John Zibert, Chief Medical Officer, noted the facility's potential to optimize production and develop new formulations. Coegin Pharma, a Swedish biotech company, plans to commercialize hair growth products in late 2025 and a pigmentation product in 2026. The company is listed on NGM Nordic SME and Börse Stuttgart, with headquarters in Lund, Sweden.

Coegin Pharma is on track to commercialize its first Follicopeptide-based product by the end of the year, marking a shift from a research-focused biotech to a revenue-generating company. Commercial-scale production is secured in Denmark, with raw materials ordered and production set to start in September. Regulatory processes are progressing, with the Product Information File submission planned for autumn. Negotiations with potential partners for initial orders are ongoing, with a focus on the EU market and other regions like the US, China, South Korea, and Brazil. The product will be delivered in a ready-to-use bottle, branded by the partner. Coegin Pharma aims to lead in hair and skin solutions, with plans to launch more products in the coming years. The company is listed on NGM Nordic SME and Börse Stuttgart, with headquarters in Lund, Sweden.

Coegin Pharma meddelar att företaget framöver endast kommer att använda engelska för sin informationsgivning, inklusive finansiella rapporter och pressmeddelanden, för att effektivisera kommunikationen med sina internationella intressenter. Tidigare material på svenska kommer fortsatt att vara tillgängligt på deras hemsida. Coegin Pharma är ett svenskt bioteknikföretag som fokuserar på innovationer för hår och hud, med planer på att lansera produkter för hårtillväxt och hudpigmentering inom de kommande åren. Företaget är noterat på NGM Nordic SME och Börse Stuttgart, med huvudkontor i Lund. Mer information finns på deras hemsida.

Coegin Pharma förbereder lanseringen av sin första produkt för hårtillväxt, baserad på Follicopeptide, med planerad lansering i slutet av 2025. Företaget har lyckats sänka produktionskostnaderna med över 80 procent och fokuserar nu på att optimera användarupplevelsen och den kommersiella attraktiviteten. En ny prototyp har utvecklats med en sprutliknande förpackning och ett låsbart klicksystem för hygienisk och effektiv applicering. Produkten har utformats efter omfattande marknadsundersökningar för att möta kund- och partnerkrav. Coegin planerar att erbjuda produkten i olika koncentrationer beroende på marknad och försäljningskanal. Kostnadsminskningen stärker företagets position i förhandlingar med partners. Coegin Pharma, med säte i Lund, är ett svenskt bioteknikbolag som utvecklar innovationer för hår och hud, med aktier noterade på NGM Nordic SME och Börse Stuttgart.

På årsstämman för Coegin Pharma AB den 22 maj 2025 fattades flera beslut. Det beslutades att ingen utdelning skulle ges för 2024 och att ansvarsfrihet beviljades styrelsen och VD:n. Jens Eriksson, Thoas Fioretos, Eva Sjökvist Saers och Erlend Skagseth omvaldes till styrelsen, med Eva Sjökvist Saers som ordförande. Örlings PricewaterhouseCoopers AB omvaldes som revisor. Styrelsearvoden fastställdes till totalt 576 000 kronor och revisorernas arvoden enligt sedvanliga normer. Riktlinjer för valberedningen fastställdes, och ett ersättningsprogram för VD:n, som kräver aktieförvärv, godkändes. Bolagsordningen ändrades för att tillåta bolagsstämmor i Stockholm. Styrelsen bemyndigades att besluta om emissioner upp till 35 miljoner SEK. Coegin Pharma är ett bioteknikföretag med fokus på produkter för hårtillväxt och hudpigmentering, med planer på att lansera dessa produkter 2025 och 2026.